Eli Lilly fell well short of Wall Street’s first-quarter expectations, and the drugmaker chopped the top end of its earnings forecast due to lower demand for COVID-19 treatments.
Lilly said it now expects 2021 adjusted earnings to range from $7.80 to $8 per share after predicting in late January a range of $7.75 to $8.40.Lilly pulled in $810 million in the quarter from sales of COVID-19 treatments and expects to bring in as much as $1.5 billion from the drugs this year. But the company also said it changed its adjusted earnings outlook mainly due to lower expected demand for the treatments and higher research and development costs.
It now recommends that care providers use bamlanivimab along with another one of its drugs, etesevimab.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: